Loading…

Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial

•Black and Hispanic patients are historically underrepresented in MS trials.•MS course and immunology differ in black and Hispanic vs white patients.•The CHIMES trial is studying ocrelizumab in black and Hispanic patients with RMS.•Baseline differences were observed for patients in CHIMES compared w...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2023-08, Vol.76, p.104794-104794, Article 104794
Main Authors: Williams, Mitzi J, Okai, Annette F, Cross, Anne H, Monson, Nancy L, Vartanian, Timothy, Thrower, Ben W, Reder, Anthony T, English, Jeffrey B, Wu, Gregory F, Bernitsas, Evanthia, Yap, Shereen, Ndrio, Jugena, Pei, Jinglan, Mowry, Ellen M, Magrini, Fabio, Acosta, Juan, Amezcua, Lilyana
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Black and Hispanic patients are historically underrepresented in MS trials.•MS course and immunology differ in black and Hispanic vs white patients.•The CHIMES trial is studying ocrelizumab in black and Hispanic patients with RMS.•Baseline differences were observed for patients in CHIMES compared with OPERA. Black/African American patients with multiple sclerosis (BpwMS) and Hispanic/Latino patients with multiple sclerosis (HpwMS), who historically have been underrepresented in multiple sclerosis (MS) clinical trials, exhibit greater disease severity and more rapid disease progression than White patients with MS (WpwMS). The lack of diversity and inclusion in clinical trials, which may be due to barriers at the system, patient and study levels, impacts the ability to effectively assess risks, benefits and treatment responses in a generalized patient population. CHIMES (Characterization of Ocrelizumab in Minorities With Multiple Sclerosis), an open-label, single-arm, multicenter, phase IV study of self-identified BpwMS and HpwMS aged 18–65 years with relapsing MS and an Expanded Disability Status Score (EDSS) of ≤5.5, was developed in collaboration with patients with MS, national advocacy groups and clinical researchers. Patients were enrolled at study centers across the US, including Puerto Rico, and 1 site in Kenya. A total of 182 patients enrolled in CHIMES: 113 (62.1%) were BpwMS, and 69 (37.9%) were HpwMS; the mean (SD) baseline EDSS score was 2.4 (1.4), and 62.6% of patients were treatment naive. Using the pooled non–BpwMS/HpwMS group in the OPERA ocrelizumab trials as a reference population, patients enrolled in CHIMES were younger, had a higher mean body mass and had a greater T2 lesion volume but similar T2 lesion number on MRI. BpwMS and HpwMS have been consistently underrepresented in clinical trials, limiting the understanding of disease biology and response to treatment in this population. Data from the CHIMES study revealed differences in demographics and some baseline disease characteristics and disease burden between BpwMS and HpwMS vs WpwMS. These differences could have an impact when assessing clinical outcomes in BpwMS and HpwMS. NCT04377555
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2023.104794